Rituxan (rituximab)

DRUG3 trials

Sponsors

Biogen, National Cancer Institute (NCI), Khyber Teaching Hospital

Conditions

Lupus Erythematosus, SystemicNon-Hodgkin's LymphomaPemphigus VulgarisRituximab (RTx)

Early Phase 1

Rituximab With Corticosteroids Versus Corticosteroids Plus Azathioprine for Moderate-to-Severe Pemphigus Vulgaris

Not yet recruitingNCT07769333

Khyber Teaching HospitalPemphigus Vulgaris, Rituximab (RTx)

Start: 2026-12-02End: 2027-11-06Target: 92Updated: 2026-08-18

Phase 2

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

CompletedNCT00076752

National Cancer Institute (NCI)Lupus Erythematosus, Systemic

Start: 2004-01-30End: 2013-10-15Updated: 2021-01-05

Phase 3

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

TerminatedNCT00057343

BiogenNon-Hodgkin's Lymphoma

Start: 2003-03-31Target: 400Updated: 2006-09-12

Related Papers

Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus

Lara D. Veeken2021-12-0122 citations